Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Jambo (J) fluctuated 61.0% in 24 hours: Trading volume surged over 900% driving high volatility

Jambo (J) fluctuated 61.0% in 24 hours: Trading volume surged over 900% driving high volatility

Bitget PulseBitget Pulse2026/03/12 11:42
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, J (Jambo) price rebounded from a low of $0.01039 to a high of $0.01656, currently reported at $0.01356 (around $0.01259 at user reference time), with a price swing amplitude reaching 61.0%. 24-hour trading volume reached $9.24 million, surging by over 900% compared to the previous level (approximately $1 million). Market capitalization is around $2.18 million, and the volume/market cap ratio exceeds 4 times.

Brief Analysis of the Abnormal Price Move

- No official announcements, major news, or large on-chain whale transfers observed within 24 hours.

- Trading volume surged from around $1 million to $9.24 million, which was the main driver, with high trading volume amplifying speculative volatility.

Market Views and Outlook

Market sentiment remains neutral to cautious, with no significant community discussions or analyst forecasts observed on X in the past 24 hours. Platforms like CoinCodex predict a short-term price range of $0.0089-0.0122, emphasizing the high risk of volatility. Going forward, continued trading volume needs to be monitored, and caution is advised regarding high volatility risks of small-cap tokens.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Novo Nordisk (NVO.US) Q2 results beat expectations and full-year guidance is raised, but concerns remain! Wegovy oral drug sales are weak, and the path to renewed growth is still uncertain

Although Novo Nordisk reported better-than-expected Q2 2026 results and raised its full-year guidance, it did not address the issue that is of most concern to Wall Street.

智通财经2026/08/05 08:01
Novo Nordisk (NVO.US) Q2 results beat expectations and full-year guidance is raised, but concerns remain! Wegovy oral drug sales are weak, and the path to renewed growth is still uncertain

Litecoin Outlook Hinges on Key Resistance Break

Cryptonewsland2026/08/05 07:48
Litecoin Outlook Hinges on Key Resistance Break